AlloVir, Inc. Stock News

AlloVir (ALVR) stock is taking off on Wednesday following an update from the U.S. Food and Drug Administration (FDA) on posoleucel. The post Why Is AlloVir (ALVR) Stock Up 30% Today?

AlloVir Inc (NASDAQ: ALVR) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to its l

AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.

AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.

Zacks Investment Research cut shares of AlloVir from a hold rating to a sell rating in a report published on Friday morning, Zacks.com reports. According to Zacks, “AlloVir…

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST. A live webcast of the fireside chat will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay will be availa

AlloVir (NASDAQ: ALVR ) reported its Q4 earnings results on Thursday, February 10, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Check out this: Insiders Buy Over $43M Of 4 Stocks Earnings AlloVir … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer Merc

AlloVir press release (ALVR): FY GAAP EPS of -$2.74 misses by $0.10.As of December 31, 2021, company had cash, cash equivalents and marketable securities of $248.1 million, compared…

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, 2021. The company also provided the outlook for 2022 across its pipeline of allogeneic, off-the-shelf, virus-specific T cell (VST) therapies for immunocompromised patients, including its lead product posoleucel, an investigational VST in development for the treatment and prevention of infections

AlloVir manufactures T cells ex vivo, off-the-shelf, for curing viral infections in HSCT patients. Click here for a review of ALVR''s manufacturing process.

AlloVir: A Comparative Study Of Its Manufacturing Process

AlloVir Inc (ALVR) shares closed today at 1.3% above its 52 week low of $10.10, giving the company a market cap of $666M. The stock is currently down 20.9% year-to-date, down 75.7% over the past 12 months, and down 59.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 34.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 669.0% The company's stock price performance over the past 12 months lags the peer average by 149.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

AlloVir (NASDAQ:ALVR) had its price objective lowered by equities research analysts at SVB Leerink from $37.00 to $32.00 in a research note issued to investors on Friday, Price Targets.com reports. The brokerage currently has an outperform rating on the stock. SVB Leerinks price objective points to a potential upside of 125.04% from the stocks previous []